Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07UGA
|
|||
| Former ID |
DNC010688
|
|||
| Drug Name |
Sphingosine-1-phosphate
|
|||
| Synonyms |
Sphingosine 1-phosphate; sphingosine-1-phosphate; 26993-30-6; D-erythro-Sphingosine-1-phosphate; C18-Sphingosine 1-phosphate; Sphing-4-enine 1-phosphate; S1P; CHEBI:37550; D-erythro-sphingosine 1-phosphate; UNII-YVE187NJ1U; Sphingosine 1-phosphic acid; (2S,3R,4E)-2-amino-3-hydroxyoctadec-4-en-1-yl dihydrogen phosphate; Sphing-4-enine-1-phosphate; YVE187NJ1U; CHEMBL225155; DUYSYHSSBDVJSM-KRWOKUGFSA-N; 4-Octadecene-1,3-diol, 2-amino-, 1-(dihydrogen phosphate), (2S,3R,4E)-; (2S,3R,4E)-2-Amino-4-octadecene-1,3-diol 1-(Dihydroge
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Acne vulgaris [ICD-11: ED80; ICD-10: L70.0; ICD-9: 706.1] | Phase 1 | [1], [2] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H38NO5P
|
|||
| Canonical SMILES |
CCCCCCCCCCCCCC=CC(C(COP(=O)(O)O)N)O
|
|||
| InChI |
1S/C18H38NO5P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(20)17(19)16-24-25(21,22)23/h14-15,17-18,20H,2-13,16,19H2,1H3,(H2,21,22,23)/b15-14+/t17-,18+/m0/s1
|
|||
| InChIKey |
DUYSYHSSBDVJSM-KRWOKUGFSA-N
|
|||
| CAS Number |
CAS 26993-30-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
8381, 841938, 3153153, 4266347, 11039024, 11538026, 14853517, 14902393, 24893757, 24899853, 26754964, 26754965, 26759550, 29214822, 39316963, 47736194, 50069271, 53790239, 56310719, 56314086, 56314115, 57358934, 79196702, 85230694, 91616005, 99431555, 103513044, 104045126, 104046551, 112629138, 113860431, 123055038, 135061792, 135651563, 137123351, 141225271, 144107094, 162223883, 163687305, 164808502, 175443701, 179205494, 226395983, 228659508, 241182370, 241375387, 250135272, 252467313
|
|||
| ChEBI ID |
CHEBI:37550
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Sphingosine-1-phosphate receptor 1 (S1PR1) | Target Info | Inhibitor | [3] |
| KEGG Pathway | FoxO signaling pathway | |||
| Sphingolipid signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| NetPath Pathway | IL4 Signaling Pathway | |||
| TGF_beta_Receptor Signaling Pathway | ||||
| IL2 Signaling Pathway | ||||
| Pathway Interaction Database | Fc-epsilon receptor I signaling in mast cells | |||
| S1P3 pathway | ||||
| S1P1 pathway | ||||
| Sphingosine 1-phosphate (S1P) pathway | ||||
| PDGFR-beta signaling pathway | ||||
| Reactome | G alpha (i) signalling events | |||
| Lysosphingolipid and LPA receptors | ||||
| WikiPathways | Signal Transduction of S1P Receptor | |||
| Small Ligand GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 911). | |||
| REF 2 | ClinicalTrials.gov (NCT01466322) A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers.. U.S. National Institutes of Health. | |||
| REF 3 | Exploration of amino alcohol derivatives as novel, potent, and highly selective sphingosine-1-phosphate receptor subtype-1 agonists. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2520-4. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.